1. Home
  2. STRO vs VYGR Comparison

STRO vs VYGR Comparison

Compare STRO & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

HOLD

Current Price

$25.06

Market Cap

338.9M

Sector

Health Care

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.85

Market Cap

194.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STRO
VYGR
Founded
2003
2013
Country
United States
United States
Employees
131
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
338.9M
194.0M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
STRO
VYGR
Price
$25.06
$3.85
Analyst Decision
Buy
Strong Buy
Analyst Count
8
3
Target Price
$26.38
$21.00
AVG Volume (30 Days)
168.4K
873.3K
Earning Date
03-23-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,135,000.00
Revenue This Year
N/A
$33.19
Revenue Next Year
$13.45
$14.68
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.52
$2.65
52 Week High
$27.96
$5.55

Technical Indicators

Market Signals
Indicator
STRO
VYGR
Relative Strength Index (RSI) 63.16 44.29
Support Level $0.76 $3.72
Resistance Level $27.96 $4.43
Average True Range (ATR) 2.15 0.27
MACD -0.08 -0.04
Stochastic Oscillator 78.98 10.18

Price Performance

Historical Comparison
STRO
VYGR

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: